PriceTargets.com logo

Soligenix - SNGX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.48 As of 01/27/2023 01:00 AM ET
▲ +0.01 (2.13%)

This chart shows the closing price for SNGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Soligenix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNGX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Soligenix in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.48.

This chart shows the closing price for SNGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Soligenix. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/25/2021Alliance Global PartnersLower TargetBuy$5.75 ➝ $3.75Low
6/1/2021B. RileyLower TargetNeutral$2.00 ➝ $1.50Low
1/28/2021B. RileyReiterated RatingHold$2.00High
12/31/2020B. RileyReiterated RatingNeutralN/A
12/23/2020Alliance Global PartnersLower TargetBuy$7.25 ➝ $5.75N/A
12/4/2020B. RileyInitiated CoverageBuy$4.00High
7/28/2020Dawson JamesDowngradeBuy ➝ Neutral$3.00 ➝ $2.00High
6/25/2020Maxim GroupInitiated CoverageBuy$4.00High
5/1/2020Maxim GroupInitiated CoverageBuy$4.00Low
12/4/2019Maxim GroupReiterated RatingBuy$4.00Medium
8/29/2019Maxim GroupReiterated RatingBuy$4.00High
5/16/2019Maxim GroupReiterated RatingBuy$4.00High
3/26/2019Maxim GroupSet TargetBuy$4.00High
12/6/2018Maxim GroupSet TargetBuy$4.00High
9/13/2018Maxim GroupReiterated RatingBuy$4.00Low
6/4/2018Maxim GroupReiterated RatingBuy$5.00Low
5/11/2018Maxim GroupSet TargetBuy$5.00Low
3/22/2018Maxim GroupSet TargetBuy$5.00High
3/16/2018HC WainwrightSet TargetHold$3.00Low
3/15/2018Maxim GroupSet TargetBuy$5.00Medium
1/31/2018HC WainwrightDowngradeBuy ➝ Neutral$5.50 ➝ $2.70Low
(Data available from 1/29/2018 forward)

News Sentiment Rating

1.55 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
Mentions as of
8/2/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
9/1/2022
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/1/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Soligenix logo
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Read More

Today's Range

Now: $0.48
Low: $0.47
High: $0.51

50 Day Range

MA: $0.53
Low: $0.40
High: $0.67

52 Week Range

Now: $0.48
Low: $0.38
High: $1.00

Volume

50,033 shs

Average Volume

82,281 shs

Market Capitalization

$20.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Soligenix?

The following Wall Street analysts have issued research reports on Soligenix in the last year:
View the latest analyst ratings for SNGX.

What is the current price target for Soligenix?

0 Wall Street analysts have set twelve-month price targets for Soligenix in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Soligenix in the next year.
View the latest price targets for SNGX.

What is the current consensus analyst rating for Soligenix?

Soligenix currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SNGX.

What other companies compete with Soligenix?

Other companies that are similar to Soligenix include Metacrine, Tempest Therapeutics, Flora Growth, eFFECTOR Therapeutics and Forte Biosciences. Learn More about companies similar to Soligenix.

How do I contact Soligenix's investor relations team?

Soligenix's physical mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company's listed phone number is (609) 538-8200 and its investor relations email address is [email protected] The official website for Soligenix is www.soligenix.com. Learn More about contacing Soligenix investor relations.